Effects of curcumin on HDL functionality

被引:146
作者
Ganjali, Shiva [1 ]
Bless, Christopher N. [2 ]
Banach, Maciej [3 ,4 ]
Pirro, Matteo [5 ]
Majeed, Muhammed [6 ]
Sahebkar, Amirhossein [7 ,8 ]
机构
[1] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Iran
[2] Univ Connecticut, Dept Nutr Sci, Storrs, CT USA
[3] Med Univ Lodz, WAM Univ Hosp Lodz, Dept Hypertens, Zeromskiego 113, Lodz, Poland
[4] PMMHRI, Lodz, Poland
[5] Univ Perugia, Dept Med, Unit Internal Med Angiol & Arteriosclerosis Dis, Perugia, Italy
[6] Sabinsa Corp, East Windsor, NJ USA
[7] Mashhad Univ Med Sci, Biotechnol Res Ctr, Mashhad, Iran
[8] Univ Western Australia, Sch Med, Perth, WA, Australia
关键词
Curcumin; High-density lipoprotein; Dyslipidemia; Atherosclerosis; Cholesterol efflux; DENSITY-LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN-A-I; C-REACTIVE PROTEIN; SERUM-AMYLOID-A; CHRONIC PULMONARY COMPLICATIONS; RANDOMIZED CONTROLLED-TRIAL; SYSTEMIC OXIDATIVE STRESS; HEAT-SHOCK-PROTEIN; QUALITY-OF-LIFE; SCAVENGER RECEPTOR;
D O I
10.1016/j.phrs.2017.02.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Curcumin, a bioactive polyphenol, is a yellow pigment of the Curcuma Tonga (turmeric) plant. Curcumin has many pharmacologic effects including antioxidant, anti-carcinogenic, anti-obesity, anti-angiogenic and anti-inflammatory properties. Recently, it has been found that curcumin affects lipid metabolism, and subsequently, may alleviate hyperlipidemia and atherosclerosis. Plasma HDL cholesterol (HDL-C) is an independent negative risk predictor of cardiovascular disease (CVD). However, numerous clinical and genetic studies have yielded disappointing results about the therapeutic benefit of raising plasma HDL-C levels. Therefore, research efforts are now focused on improving HDL functionality, independent of HDL-C levels. The quality of HDL particles can vary considerably due to heterogeneity in composition. Consistent with its complexity in composition and metabolism, a wide range of biological activities is reported for HDL, including antioxidant, anti-glycation, anti-inflammatory, anti-thrombotic, anti-apoptotic and immune modulatory activities. Protective properties of curcumin may influence HDL functionality; therefore, we reviewed the literature to determine whether curcumin can augment HDL function. In this review, we concluded that curcumin may modulate markers of HDL function, such as apo-AI, CETP, LCAT, PON1, MPO activities and levels. Curcumin may subsequently improve conditions in which HDL is dysfunctional and may have potential as a therapeutic drug in future. Further clinical trials with bioavailability-improved formulations of curcumin are warranted to examine its effects on lipid metabolism and HDL function. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:208 / 218
页数:11
相关论文
共 129 条
[1]  
Abdollahi E., 2017, J CELL PHYS IN PRESS
[2]   Identification of scavenger receptor SR-BI as a high density lipoprotein receptor [J].
Acton, S ;
Rigotti, A ;
Landschulz, KT ;
Xu, SZ ;
Hobbs, HH ;
Krieger, M .
SCIENCE, 1996, 271 (5248) :518-520
[3]   The roles of different pathways in the release of cholesterol from macrophages [J].
Adorni, Maria Pia ;
Zimetti, Francesca ;
Billheimer, Jeffrey T. ;
Wang, Nan ;
Rader, Daniel J. ;
Phillips, Michael C. ;
Rothblat, George H. .
JOURNAL OF LIPID RESEARCH, 2007, 48 (11) :2453-2462
[4]   Modulatory Effect of Phytoestrogens and Curcumin on Induction of Annexin 1 in Human Peripheral Blood Mononuclear Cells and their Inhibitory Effect on Secretory Phospholipase A2 [J].
Ahmad, Waqas ;
Kumolosasi, Endang ;
Jantan, Ibrahim ;
Jasamai, Malina ;
Salim, Emil .
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2014, 13 (02) :171-177
[5]  
Amel Z. Narges, 2016, CURR PHARM DESIGN, V22, P1
[6]   Bioavailability of curcumin: Problems and promises [J].
Anand, Preetha ;
Kunnumakkara, Ajaikumar B. ;
Newman, Robert A. ;
Aggarwal, Bharat B. .
MOLECULAR PHARMACEUTICS, 2007, 4 (06) :807-818
[7]  
[Anonymous], ALTERN MED
[8]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[9]   Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality [J].
Barylski, Marcin ;
Toth, Peter P. ;
Nikolic, Dragana ;
Banach, Maciej ;
Rizzo, Manfredi ;
Montalto, Giuseppe .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 28 (03) :453-461
[10]   The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport [J].
Bergt, C ;
Pennathur, S ;
Fu, XY ;
Byun, J ;
O'Brien, K ;
McDonald, TO ;
Singh, P ;
Anantharamaiah, GM ;
Chait, A ;
Brunzell, J ;
Geary, RL ;
Oram, JF ;
Heinecke, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (35) :13032-13037